NM_002863.5:c.772+16G>T

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1

The NM_002863.5(PYGL):​c.772+16G>T variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0266 in 1,593,836 control chromosomes in the GnomAD database, including 899 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.023 ( 74 hom., cov: 32)
Exomes 𝑓: 0.027 ( 825 hom. )

Consequence

PYGL
NM_002863.5 intron

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:6

Conservation

PhyloP100: 0.0200

Publications

3 publications found
Variant links:
Genes affected
PYGL (HGNC:9725): (glycogen phosphorylase L) This gene encodes a homodimeric protein that catalyses the cleavage of alpha-1,4-glucosidic bonds to release glucose-1-phosphate from liver glycogen stores. This protein switches from inactive phosphorylase B to active phosphorylase A by phosphorylation of serine residue 15. Activity of this enzyme is further regulated by multiple allosteric effectors and hormonal controls. Humans have three glycogen phosphorylase genes that encode distinct isozymes that are primarily expressed in liver, brain and muscle, respectively. The liver isozyme serves the glycemic demands of the body in general while the brain and muscle isozymes supply just those tissues. In glycogen storage disease type VI, also known as Hers disease, mutations in liver glycogen phosphorylase inhibit the conversion of glycogen to glucose and results in moderate hypoglycemia, mild ketosis, growth retardation and hepatomegaly. Alternative splicing results in multiple transcript variants encoding different isoforms.[provided by RefSeq, Feb 2011]
PYGL Gene-Disease associations (from GenCC):
  • glycogen storage disease VI
    Inheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), G2P, PanelApp Australia, Genomics England PanelApp, Orphanet, Ambry Genetics

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.77).
BP6
Variant 14-50920940-C-A is Benign according to our data. Variant chr14-50920940-C-A is described in ClinVar as Benign. ClinVar VariationId is 258847.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.0833 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
PYGLNM_002863.5 linkc.772+16G>T intron_variant Intron 6 of 19 ENST00000216392.8 NP_002854.3 P06737-1
PYGLNM_001163940.2 linkc.670+16G>T intron_variant Intron 5 of 18 NP_001157412.1 P06737-2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
PYGLENST00000216392.8 linkc.772+16G>T intron_variant Intron 6 of 19 1 NM_002863.5 ENSP00000216392.7 P06737-1
PYGLENST00000532462.5 linkc.772+16G>T intron_variant Intron 6 of 19 1 ENSP00000431657.1 E9PK47
PYGLENST00000544180.6 linkc.670+16G>T intron_variant Intron 5 of 18 2 ENSP00000443787.1 P06737-2
PYGLENST00000553872.1 linkn.573+16G>T intron_variant Intron 1 of 2 5

Frequencies

GnomAD3 genomes
AF:
0.0232
AC:
3523
AN:
152180
Hom.:
75
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00676
Gnomad AMI
AF:
0.00768
Gnomad AMR
AF:
0.0484
Gnomad ASJ
AF:
0.0112
Gnomad EAS
AF:
0.0902
Gnomad SAS
AF:
0.0516
Gnomad FIN
AF:
0.0203
Gnomad MID
AF:
0.0222
Gnomad NFE
AF:
0.0216
Gnomad OTH
AF:
0.0225
GnomAD2 exomes
AF:
0.0316
AC:
7930
AN:
251322
AF XY:
0.0324
show subpopulations
Gnomad AFR exome
AF:
0.00769
Gnomad AMR exome
AF:
0.0325
Gnomad ASJ exome
AF:
0.00963
Gnomad EAS exome
AF:
0.0985
Gnomad FIN exome
AF:
0.0199
Gnomad NFE exome
AF:
0.0225
Gnomad OTH exome
AF:
0.0249
GnomAD4 exome
AF:
0.0269
AC:
38825
AN:
1441538
Hom.:
825
Cov.:
30
AF XY:
0.0276
AC XY:
19792
AN XY:
718364
show subpopulations
African (AFR)
AF:
0.00776
AC:
256
AN:
32992
American (AMR)
AF:
0.0344
AC:
1536
AN:
44688
Ashkenazi Jewish (ASJ)
AF:
0.0113
AC:
293
AN:
25988
East Asian (EAS)
AF:
0.112
AC:
4443
AN:
39618
South Asian (SAS)
AF:
0.0514
AC:
4412
AN:
85802
European-Finnish (FIN)
AF:
0.0207
AC:
1106
AN:
53400
Middle Eastern (MID)
AF:
0.0235
AC:
134
AN:
5706
European-Non Finnish (NFE)
AF:
0.0229
AC:
25011
AN:
1093626
Other (OTH)
AF:
0.0274
AC:
1634
AN:
59718
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.487
Heterozygous variant carriers
0
1726
3452
5179
6905
8631
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
1040
2080
3120
4160
5200
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0232
AC:
3527
AN:
152298
Hom.:
74
Cov.:
32
AF XY:
0.0248
AC XY:
1846
AN XY:
74470
show subpopulations
African (AFR)
AF:
0.00693
AC:
288
AN:
41554
American (AMR)
AF:
0.0483
AC:
739
AN:
15288
Ashkenazi Jewish (ASJ)
AF:
0.0112
AC:
39
AN:
3472
East Asian (EAS)
AF:
0.0900
AC:
467
AN:
5188
South Asian (SAS)
AF:
0.0512
AC:
247
AN:
4826
European-Finnish (FIN)
AF:
0.0203
AC:
216
AN:
10618
Middle Eastern (MID)
AF:
0.0238
AC:
7
AN:
294
European-Non Finnish (NFE)
AF:
0.0216
AC:
1470
AN:
68034
Other (OTH)
AF:
0.0223
AC:
47
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.497
Heterozygous variant carriers
0
165
330
496
661
826
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
46
92
138
184
230
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0198
Hom.:
55
Bravo
AF:
0.0234
Asia WGS
AF:
0.0710
AC:
247
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Benign:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:3
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Jul 26, 2017
Mayo Clinic Laboratories, Mayo Clinic
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

May 18, 2021
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Glycogen storage disease, type VI Benign:2
Jan 30, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Nov 07, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not specified Benign:1
-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.77
CADD
Benign
1.7
DANN
Benign
0.64
PhyloP100
0.020
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.1
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs17123173; hg19: chr14-51387658; API